Structure Therapeutics Inc. (GPCR)
- Previous Close
35.82 - Open
36.35 - Bid 35.75 x 100
- Ask 36.01 x 200
- Day's Range
35.67 - 38.07 - 52 Week Range
21.79 - 75.02 - Volume
444,029 - Avg. Volume
586,437 - Market Cap (intraday)
1.678B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.43 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
76.89
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
structuretx.comRecent News: GPCR
Performance Overview: GPCR
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GPCR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GPCR
Valuation Measures
Market Cap
1.68B
Enterprise Value
1.25B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.16%
Return on Equity (ttm)
-33.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-89.62M
Diluted EPS (ttm)
-2.43
Balance Sheet and Cash Flow
Total Cash (mrq)
467.32M
Total Debt/Equity (mrq)
1.20%
Levered Free Cash Flow (ttm)
-51.38M
Research Analysis: GPCR
Company Insights: GPCR
GPCR does not have Company Insights